AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11392406 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa suspension in Ora Plus/Ora Sweet
Number of subjects: 15
Study 11392406 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa suspension with ascorbic acid
Number of subjects: 15
Study 11392406 — intervention group
Group type: COMPARATOR
Intervention: Levodopa-carbidopa suspension
Number of subjects: 15
Study 8730003 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (100 micrograms)
Number of subjects: 8
Study 8730003 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone (500 micrograms)
Number of subjects: 8
Study 8730003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1846438 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous schedule (daily estrogen and progestin)
Number of subjects: 48
Study 1846438 — intervention group
Group type: COMPARATOR
Intervention: Sequential schedule (conjugated estrogen on days 1‐25, medroxyprogesterone acetate on days 16‐25)
Number of subjects: 48
Study 6356630 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid (daily dose 600 mg)
Number of subjects: 60
Study 6356630 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen (daily dose 1200 mg)
Number of subjects: 60
Study 31684169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based stress-management program for four weeks
Number of subjects: 56
Study 31684169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study 27271728 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace (integrated, person-centered primary care and support)
Number of subjects: 1456
Study 25719617 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (imipramine 75 mg/d + pregabalin 300 mg/d)
Number of subjects: 69
Study 25719617 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (75 mg/d)
Number of subjects: 69
Study 25719617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg/d)
Number of subjects: 69
Study 25719617 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 69
Study 24733680 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR)
Number of subjects: 118
Study 24733680 — intervention group
Group type: COMPARATOR
Intervention: Weekly problem-solving group intervention
Number of subjects: 118
Study 22282884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 mL daily for 10 days)
Number of subjects: 1070
Study 22282884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution, intravenous infusion for 10 days)
Number of subjects: 1070
Study 22282884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 1070
Study 22282884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1070
Study 19773378 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaNp63 positive lesions
Number of subjects: 152
Study 19773378 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaNp63 positive lesions, podoplanin positive lesions, and EIC
Number of subjects: 152
Study 17498580 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder (ILR) with 1-year monitoring (n = 26)
Number of subjects: 50
Study 17498580 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (24‐h Holter recording, 4-week ambulatory ECG monitoring, electrophysiological study) (n = 24)
Number of subjects: 50
Study 17498580 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder (ILR)
Number of subjects: 50
Study 17498580 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy
Number of subjects: 50
Study 15626943 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (HBV) plus measles vaccine
Number of subjects: 876
Study 15626943 — intervention group
Group type: COMPARATOR
Intervention: Measles vaccine only
Number of subjects: 876
Study 15626943 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (HBV)
Number of subjects: 876
Study 11731687 — intervention group
Group type: COMPARATOR
Intervention: Hand-driven pump (control group)
Number of subjects: 454
Study 11731687 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPS 0.2 (computer-assisted dilatation at 0.2 bar/s)
Number of subjects: 454
Study 11731687 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPS 1.0 (computer-assisted dilatation at 1.0 bar/s)
Number of subjects: 454
Study 9203566 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (6 x 10(‐9)‐6 x 10(‐6) M)
Number of subjects: 7
Study 9203566 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (1.24 x 10(‐4) M)
Number of subjects: 7
Study 9203566 — intervention group
Group type: COMPARATOR
Intervention: Control (isoosmolar saline)
Number of subjects: 7
Study 7962303 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 122
Study 7962303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 3630180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine alone
Number of subjects: 218
Study 3630180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine with bacampicillin
Number of subjects: 218
Study 3630180 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal mucosa)
Number of subjects: 218
Study 31680054 — intervention group
Group type: EXPERIMENTAL
Intervention: DMLS
Number of subjects: 32
Study 31680054 — intervention group
Group type: COMPARATOR
Intervention: CAST
Number of subjects: 32
Study 29658810 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) or glycopyrronium (GLY)
Number of subjects: 4389
Study 29658810 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in wheeze on Day 7
Number of subjects: 4389
Study 29658810 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime symptoms and wheeze on Day 14
Number of subjects: 4389
Study 29658810 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in nighttime symptoms and wheeze on Day 7
Number of subjects: 4389
Study 29658810 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime symptoms, sputum and wheeze on Day 14
Number of subjects: 4389
Study 27265388 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (>85% cocoa), 40 g/day for 2 weeks
Number of subjects: 38
Study 27265388 — intervention group
Group type: COMPARATOR
Intervention: Milk chocolate (<35% cocoa), 40 g/day for 2 weeks
Number of subjects: 38
Study 27265388 — intervention group
Group type: COMPARATOR
Intervention: NASH patients compared to controls
Number of subjects: 38
Study 24518826 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg⁻¹ body mass)
Number of subjects: 10
Study 24518826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23875965 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (conjugated estrogen)
Number of subjects: 62
Study 23875965 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 62
Study 23875965 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study 23875965 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (conjugated estrogen) plus progesterone (medroxyprogesterone acetate; MPA)
Number of subjects: 62
Study 23875965 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 62
Study 20300126 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-Guar group (27 patients)
Number of subjects: 48
Study 20300126 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment group (21 patients)
Number of subjects: 48
Study 18836927 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic day treatment programme (5 months duration, including psychodynamic and cognitive-based therapy in group/individual settings)
Number of subjects: 66
Study 18836927 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 66
Study 16651155 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with propofol infusion (LAP)
Number of subjects: 32
Study 16651155 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 32
Study 12796759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 405
Study 12796759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 11040718 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal education including information about newborn sickle cell screening
Number of subjects: 647
Study 11040718 — intervention group
Group type: COMPARATOR
Intervention: No prenatal education about newborn sickle cell screening (control group)
Number of subjects: 647
Study 9335416 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg
Number of subjects: 43
Study 9335416 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 43
Study 9335416 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (combined with ACE inhibitor)
Number of subjects: 43
Study 8409641 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha‐OH‐D3 (1.0 micrograms/day)
Number of subjects: 19
Study 8409641 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated)
Number of subjects: 19
Study 3021083 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride (alpha 2‐adrenergic receptor agonist)
Number of subjects: 47
Study 3021083 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine (alpha 2‐adrenergic receptor antagonist)
Number of subjects: 47
Study 30665850 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bilateral ESPB (0.25 mL/kg/side of ropivacaine 0.5%)
Number of subjects: 67
Study 30665850 — intervention group
Group type: COMPARATOR
Intervention: Control group (IV morphine, 0.5 mg/h and IV nefopam, 100 mg/24 h)
Number of subjects: 67
Study 30665850 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bilateral ESPB
Number of subjects: 67
Study 30665850 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 27699819 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA growth curve model with a threshold of 0.37 ng/ml/year
Number of subjects: 68330
Study 27699819 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA growth curve model with a threshold of 0.99 ng/ml/year in African-American men (AA)
Number of subjects: 68330
Study 27699819 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA rate
Number of subjects: 68330
Study 26145824 — intervention group
Group type: EXPERIMENTAL
Intervention: DTI-incorporated neuronavigation during surgery (24 patients)
Number of subjects: 46
Study 26145824 — intervention group
Group type: COMPARATOR
Intervention: Surgery without neuronavigation (22 patients)
Number of subjects: 46
Study 26145824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DTI and control)
Number of subjects: 46
Study 23315904 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 2013
Study 23315904 — intervention group
Group type: COMPARATOR
Intervention: PES
Number of subjects: 2013
Study 23315904 — intervention group
Group type: COMPARATOR
Intervention: EES
Number of subjects: 2013
Study 23315904 — intervention group
Group type: COMPARATOR
Intervention: ZES-S
Number of subjects: 2013
Study 21273209 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger group (mean age 25 ± 6 years)
Number of subjects: 60
Study 21273209 — intervention group
Group type: COMPARATOR
Intervention: Older group (mean age 64 ± 4 years)
Number of subjects: 60
Study 19172243 — intervention group
Group type: EXPERIMENTAL
Intervention: Trientine (600 mg orally twice daily)
Number of subjects: 30
Study 19172243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16179401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint training for 7 weeks
Number of subjects: 15
Study 16179401 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 15
Study 15488969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine solution
Number of subjects: 30
Study 15488969 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 11178766 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic esophagogastric placement (EGP)
Number of subjects: 101
Study 11178766 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic retrogastric placement (RGP)
Number of subjects: 101
Study 9494441 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning label
Number of subjects: 0
Study 9494441 — intervention group
Group type: EXPERIMENTAL
Intervention: Information label
Number of subjects: 0
Study 9494441 — intervention group
Group type: COMPARATOR
Intervention: No label
Number of subjects: 0
Study 7755459 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (quinapril 20 mg)
Number of subjects: 12
Study 7755459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3291439 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol‐17‐propionate (group A)
Number of subjects: 21
Study 3291439 — intervention group
Group type: COMPARATOR
Intervention: 0.25% fluocortolone trimethyl acetate (group B)
Number of subjects: 21
Study 3291439 — intervention group
Group type: COMPARATOR
Intervention: 0.25% fluocortolone trimethyl acetate + 0.25% fluocortolone capronate (group C)
Number of subjects: 21
Study 1539143 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic digoxin
Number of subjects: 111
Study 1539143 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic digoxin (Control)
Number of subjects: 111
Study 332089 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcinonide cream
Number of subjects: 44
Study 332089 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate cream
Number of subjects: 44
Study 31356721 — intervention group
Group type: EXPERIMENTAL
Intervention: High Ligation (HL)
Number of subjects: 197
Study 31356721 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Vascular Ligation (CVL)
Number of subjects: 197
Study 31356721 — intervention group
Group type: COMPARATOR
Intervention: Preoperative imaging for CVL
Number of subjects: 197
Study 31063408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 28532891 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Myofascial Techniques (IMT)
Number of subjects: 44
Study 28532891 — intervention group
Group type: COMPARATOR
Intervention: Kinesio Tape (KT)
Number of subjects: 44
Study 28532891 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS (Control)
Number of subjects: 44
Study 28532891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Pressure Threshold (PPT)
Number of subjects: 44
Study 26500862 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UVB (NBUVB) phototherapy at a fixed dose of 250 mJ/cm² three times a week for 4 weeks
Number of subjects: 100
Study 26500862 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UVB (NBUVB) phototherapy
Number of subjects: 100
Study 26500862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 100
Study 23509322 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus paclitaxel
Number of subjects: 0
Study 23509322 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 0
Study 21692253 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with preincisional paravertebral nerve block
Number of subjects: 40
Study 21692253 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 40
Study 19361782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Recovery Intervention (CRI)
Number of subjects: 66
Study 19361782 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 66
Study 16669305 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly ultrasound combined with standard care
Number of subjects: 0
Study 16669305 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 15606390 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (5‐aminlevulinic acid 30 mg/kg and red light)
Number of subjects: 68
Study 15606390 — intervention group
Group type: COMPARATOR
Intervention: Argon plasma coagulation (administered at a power setting of 65 W)
Number of subjects: 68
Study 11685183 — intervention group
Group type: EXPERIMENTAL
Intervention: J&J Crown stent
Number of subjects: 203
Study 11685183 — intervention group
Group type: COMPARATOR
Intervention: NIR stent
Number of subjects: 203
Study 9676024 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 42
Study 9676024 — intervention group
Group type: COMPARATOR
Intervention: Molgramostim
Number of subjects: 42
Study 9676024 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim and Molgramostim
Number of subjects: 42
Study 8742796 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT (naturally occurring short‐acting hallucinogen), dosage and duration not specified
Number of subjects: 0
Study 8742796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2650751 — intervention group
Group type: EXPERIMENTAL
Intervention: Wagner‐Nelson (WN) method
Number of subjects: 0
Study 2650751 — intervention group
Group type: EXPERIMENTAL
Intervention: Hendeles‐Weinberger modification of the WN (HW)
Number of subjects: 0
Study 2650751 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptotic WN (AWN) method
Number of subjects: 0
Study 2650751 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear regression (NL) method
Number of subjects: 0
Study 2650751 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear regression on cumulative sum of AUCs (AUCNL)
Number of subjects: 0
Study 31992604 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealthcare solution (Telekit with tablet, digital blood pressure monitor, and scale)
Number of subjects: 274
Study 31992604 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealthcare solution
Number of subjects: 274
Study 31992604 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 274
Study 31199103 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 31
Study 31199103 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular rehabilitation)
Number of subjects: 31
Study 31199103 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 31
Study 28075499 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning applied to the arm
Number of subjects: 360
Study 28075499 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning applied to the thigh
Number of subjects: 360
Study 28075499 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 mm Hg to the arm)
Number of subjects: 360
Study 28075499 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (arm or thigh)
Number of subjects: 360
Study 26636278 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training with superimposed EMS (S+E)
Number of subjects: 20
Study 26636278 — intervention group
Group type: COMPARATOR
Intervention: Strength training without EMS (S)
Number of subjects: 20
Study 23219699 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to misinformation (misleading photograph)
Number of subjects: 800
Study 23219699 — intervention group
Group type: EXPERIMENTAL
Intervention: Misinformation introduced after the event
Number of subjects: 800
Study 25729661 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A (40 Ipsen units per injection)
Number of subjects: 50
Study 25729661 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 50
Study 18155484 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltrations (BI) with 1.7 mL of 4% articaine with 1:100,000 adrenaline
Number of subjects: 0
Study 18155484 — intervention group
Group type: COMPARATOR
Intervention: Inferior alveolar nerve blocks (IANB)
Number of subjects: 0
Study 16686875 — intervention group
Group type: EXPERIMENTAL
Intervention: Female Narrator Voice
Number of subjects: 33
Study 16686875 — intervention group
Group type: EXPERIMENTAL
Intervention: Female-stereotyped narratives
Number of subjects: 33
Study 16686875 — intervention group
Group type: EXPERIMENTAL
Intervention: Narratives rated as Plausible
Number of subjects: 33
Study 14595085 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI breakfast
Number of subjects: 37
Study 14595085 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI breakfast with added sucrose
Number of subjects: 37
Study 14595085 — intervention group
Group type: COMPARATOR
Intervention: High-GI breakfast
Number of subjects: 37
Study 14595085 — intervention group
Group type: COMPARATOR
Intervention: Habitual breakfast
Number of subjects: 37
Study 11353990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 800 mg/day with interferon
Number of subjects: 18
Study 11353990 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 18
Study 9610579 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 3270
Study 9610579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3270
Study 7761010 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.01 mg/kg) with a primer of 0.003 mg/kg of buprenorphine
Number of subjects: 300
Study 7761010 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.01 mg/kg) with a primer of 0.5 mg/kg of ketorolac
Number of subjects: 300
Study 7761010 — intervention group
Group type: COMPARATOR
Intervention: Control group (Buprenorphine only, no primer)
Number of subjects: 300
Study 3186087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum treatment with ampicillin and gentamicin during labor
Number of subjects: 45
Study 3186087 — intervention group
Group type: COMPARATOR
Intervention: Postpartum treatment
Number of subjects: 45
Study 31448420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen low dose
Number of subjects: 158
Study 31448420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen high dose
Number of subjects: 158
Study 31448420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158